Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.

The Journal of biological chemistry - 5 Aug 2011

Jay Steven M, Kurtagic Elma, Alvarez Luis M, de Picciotto Seymour, Sanchez Edgar, Hawkins Jessica F, Prince Robin N, Guerrero Yadir, Treasure Carolyn L, Lee Richard T, Griffith Linda G

Abstract excerpt

The ErbB receptor family is dysregulated in many cancers, and its therapeutic manipulation by targeted antibodies and kinase inhibitors has resulted in effective chemotherapies. However, many malignancies remain refractory to current interventions. We describe a new approach that directs ErbB receptor interactions, resulting in biased signaling and phenotypes. Due to known receptor-ligand affinities and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Ligands

Share to Neuregulin-1

Share to Protein Engineering

Share to Receptor, ErbB-3

Share to Surface Plasmon Resonance

Source

Open in PubMed Open full text

Identifiers

PMID: 21622572
DOI: 10.1074/jbc.M111.221093
PMCID: PMC3149363

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.PMID 21622572Read ↗

Targeting ErbB receptor signaling: A pan-ErbB approach to cancerSemantic proximity Read ↗

ErbB/HER family in cancer immunology: therapeutic advances and mechanismsSemantic proximity Read ↗

ErbB receptors: from oncogenes to targeted cancer therapiesSemantic proximity Read ↗

Therapeutic targeting of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward.Semantic proximity Read ↗

ErbB-targeted therapeutic approaches in human cancerSemantic proximity Read ↗

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.